Methods of making low odor choline salts of an organic compound, for example, choline ellagate compound(s), and uses and formulations thereof.

The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof.

The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof.

The present invention relates to a method for preparing compounds having a 16-oxabicyclo[10.3.1]pentadecene skeleton, specifically 14-methyl-16-oxabicyclo[10.3.1]pentadecenes, and conversion products thereof.

The present invention relates to a method for preparing compounds having a 16-oxabicyclo[10.3.1]pentadecene skeleton, specifically 14-methyl-16-oxabicyclo[10.3.1]pentadecenes, and conversion products thereof.

The present invention relates to chlorinated naphthalenetetracarboxylic acid derivatives, preparation thereof and use thereof as charge transport materials, exciton transport materials or emitter materials.

The present invention relates to chlorinated naphthalenetetracarboxylic acid derivatives, preparation thereof and use thereof as charge transport materials, exciton transport materials or emitter materials.

The present invention relates to cyanated compounds of the formula (I) wherein at least one of the radicals R.sup.2, R.sup.3, R.sup.4 and R.sup.5 is CN, and the remaining radicals are selected from hydrogen, chlorine and bromine; X is O, S, SO or SO.sub.2; m is 0, 1, 2, 3 or 4; R.sup.1 is selected from bromine, chlorine, cyano, NR.sup.aR.sup.b, C.sub.1-C.sub.24-alkyl, C.sub.1-C.sub.24-haloalkyl, C.sub.1-C.sub.24-alkoxy, C.sub.1-C.sub.24-haloalkoxy, C.sub.3-C.sub.24-cycloalkyl, heterocycloalkyl, heteroaryl, C.sub.6-C.sub.24-aryl, C.sub.6-C.sub.24-aryloxy, C.sub.6-C.sub.24-aryl-C.sub.1-C.sub.10-alkylene, etc.; A is a diradical selected from diradicals of the general formulae (A.1), (A.2), (A.3), and (A.4) wherein R.sup.6, (R.sup.7).sub.n, (R.sup.8).sub.o and (R.sup.9).sub.p are as defined in the claims and in the description. The invention further relates to color converters comprising at least one polymer as a matrix material and at least one cyanated compound of formula (I) or mixtures thereof as a fluorescent dye, to the use of the color converters and to lighting devices comprising at least one LED and at least one color converter.

The present invention relates to cyanated compounds of the formula (I) wherein at least one of the radicals R.sup.2, R.sup.3, R.sup.4 and R.sup.5 is CN, and the remaining radicals are selected from hydrogen, chlorine and bromine; X is O, S, SO or SO.sub.2; m is 0, 1, 2, 3 or 4; R.sup.1 is selected from bromine, chlorine, cyano, NR.sup.aR.sup.b, C.sub.1-C.sub.24-alkyl, C.sub.1-C.sub.24-haloalkyl, C.sub.1-C.sub.24-alkoxy, C.sub.1-C.sub.24-haloalkoxy, C.sub.3-C.sub.24-cycloalkyl, heterocycloalkyl, heteroaryl, C.sub.6-C.sub.24-aryl, C.sub.6-C.sub.24-aryloxy, C.sub.6-C.sub.24-aryl-C.sub.1-C.sub.10-alkylene, etc.; A is a diradical selected from diradicals of the general formulae (A.1), (A.2), (A.3), and (A.4) wherein R.sup.6, (R.sup.7).sub.n, (R.sup.8).sub.o and (R.sup.9).sub.p are as defined in the claims and in the description. The invention further relates to color converters comprising at least one polymer as a matrix material and at least one cyanated compound of formula (I) or mixtures thereof as a fluorescent dye, to the use of the color converters and to lighting devices comprising at least one LED and at least one color converter.

The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof.